BioSpace News Archive

Atea Pharmaceuticals, Inc. confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of Atea’s programs.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Ms. Zhao Yan, Chairperson & CEO of Bloomage Biotech, attended the 2023 China-Arab Entrepreneurs Summit in Dubai, United Arab Emirates, as a Chinese entrepreneur representative.

Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”) today announced encouraging results from it’s completed pre-clinical CHRP study conducted with McMaster University evaluating PGX-processed yeast beta glucan (PGX-YBG) as a potential therapeutic option for individuals suffering from interstitial lung diseases (ILD).

AXIM Biotechnologies, Inc., an international healthcare diagnostic solutions development company, announced the appointment of Kurt Phinney as its new Chief Operating Officer.

Hillhurst Biopharmaceuticals, Inc. (“Hillhurst”) today announced that the last participant has completed the study protocol of its U.S. Phase 1 clinical trial of HBI-002, an oral low dose carbon monoxide (CO) therapeutic candidate.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

GENFIT announced the publication of the development and validation of NIS2+™ in the Journal of Hepatology.

CooperCompanies, will participate in the Jefferies Healthcare Conference on Thursday, June 8, 2023.

INOVIO (NASDAQ:INO) today announced that the European Commission (EC) has granted orphan drug designation for INO-3107, the company’s product candidate for the treatment of Recurrent Respiratory Papillomatosis (RRP).